A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2018; you can also visit the original URL.
The file type is
About 10~25% patients with herpes zoster suffers from postherpetic neuralgia (PHN). Yet, there is no certain treatment for PHN. Ketamine, an N-methyl-D-aspartate receptor (NMDA) antagonist, plays an important role in the central sensitization. In this aspect, we tried to find out the effect of IV ketamine in herpes zoster patients who suffered from PHN. Methods: 40 herpes zoster patients with Visual Analogue Scale (VAS) > 5 after the antiviral, antidepressant and nerve block therapy over 4doi:10.19070/2332-2780-1500037 fatcat:ppoqvdtxhbe77f7xjwlb5xkvh4